[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554844":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":54,"collaborators":19,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":19,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":19,"enrollmentInfo":65,"targetDuration":19,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DCR-PDL1","EXPERIMENTAL","Participants will receive multiple IV doses of DCR-PDL1 during each treatment cycle.",[13],"Drug: DCR-PDL1",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Solution for IV Infusion",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[31,45],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":19},"NEXT Oncology","RECRUITING","Irving","Texas","75039","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-96.94889,32.81402,{"lat":43,"lon":42},{"facility":46,"status":33,"city":47,"state":35,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":19},"Next Oncology","San Antonio","78229",{"type":40,"coordinates":50},[51,52],-98.49363,29.42412,{"lat":52,"lon":51},{"type":55,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100554844","phase-1-safety-tolerability-and-pharmacokinetics-of-dcr-pdl1-in-adults-with-solid-tumors-100554844",false,"NCT06504368","Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors","An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-PDL1 in Adults With Solid Tumors","Inclusion Criteria:\n\n* Male or female adults, aged greater than or equal to (≥) 18 years.\n* Participants are required to have a documented, locally advanced or metastatic solid tumor malignancy, or non-Hodgkin's lymphoma\n\n  * that is refractory to standard therapy known to provide clinical benefit for their condition OR\n  * have demonstrated evidence of disease progression or relapse, via imaging, during or following standard therapy known to provide clinical benefit for their condition, OR\n  * have demonstrated intolerance to standard therapy known to provide clinical benefit for their condition. OR\n  * for which no standard therapy is available\n* Measurable disease according to RECIST version 1.1.\n* Malignancy not currently amenable to surgical intervention.\n* ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months at the time of signing the informed consent.\n* Other protocol defined inclusion criteria could apply\n\nExclusion Criteria:\n\n* Participants with known CNS or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or symptoms suggesting CNS involvement for which treatment is required.\n* Other protocol defined exclusion criteria could apply","ALL","18 Years",{"count":66,"type":67},32,"ESTIMATED","INTERVENTIONAL",[70],"PHASE1","The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.",[73],"Solid Tumors, Adult","2025-11-04",{"date":76,"type":77},"2025-11-06","ACTUAL",{"date":79,"type":77},"2024-05-29",{"date":81,"type":67},"2027-12-31",{"name":83,"class":6},"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",2]